Roche has recently announced the completion of the acquisition of LumiraDx’s point-of-care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation.
Through this acquisition, Roche complements its diagnostics portfolio with a simple-to-use platform that consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with the future potential to expand into molecular testing. The innovative solution will allow Roche to further expand its offering in decentralised patient care and drive global access to timely and actionable diagnostic results.
“Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low- and middle-income countries,” said Matt Sause, CEO of Roche Diagnostics.
Veronique Ameye, Chief Executive Officer of LumiraDx, added: “We are absolutely delighted to continue our journey as part of Roche Diagnostics. Being an integral part of the Roche network opens the door to realising the full potential of our point-of-care technology, and to increasing patient access to community-based healthcare around the world. We look forward to writing the next chapter in our shared efforts to deliver even greater impact for patients.”
Roche announced the signing of its agreement to acquire LumiraDx’s Point of Care technology at the end of 2023.
As part of the acquisition, Roche will continue to partner with the Bill & Melinda Gates Foundation on the further expansion of the platform’s molecular diagnostic capabilities through the development of an innovative and rapid point of care molecular tuberculosis test.